Related Experiment Video
Updated: Sep 2, 2025

An Optimized Protocol for Electrophoretic Mobility Shift Assay Using Infrared Fluorescent Dye-labeled Oligonucleotides
Published on: November 29, 2016
A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor
Valerio Benedetti1, Federica Banfi1,2, Mattia Zaghi1
1Stem Cell and Neurogenesis Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Abstract:
Current therapies remain unsatisfactory in preventing the recurrence of glioblastoma multiforme (GBM), which leads to poor patient survival. By rational engineering of the transcription factor SOX2, a key promoter of GBM malignancy, together with the Kruppel-associated box and DNA methyltransferase3A/L catalytic domains, we generated a synthetic repressor named SOX2 epigenetic silencer (SES), which induces the transcriptional silencing of its original targets. By doing so, SES kills both glioma cell lines and patient-derived cancer stem cells in vitro and in vivo. SES expression, through local viral delivery in mouse xenografts, induces strong regression of human tumors and survival rescue. Conversely, SES is not harmful to neurons and glia, also thanks to a minimal promoter that restricts its expression in mitotically active cells, rarely present in the brain parenchyma. Collectively, SES produces a significant silencing of a large fraction of the SOX2 transcriptional network, achieving high levels of efficacy in repressing aggressive brain tumors.
Insights
A novel synthetic repressor, SOX2 epigenetic silencer (SES), effectively targets glioblastoma multiforme (GBM) by silencing SOX2. This approach shows promise in killing cancer cells and tumors while sparing healthy brain cells.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Glioblastoma multiforme (GBM) recurrence leads to poor patient survival.
- Current therapies are insufficient for preventing GBM recurrence.
- SOX2 is a key transcription factor promoting GBM malignancy.
Purpose of the Study:
- To engineer a synthetic repressor targeting SOX2 for GBM treatment.
- To evaluate the efficacy and safety of the SOX2 epigenetic silencer (SES) in preclinical models.
Main Methods:
- Rational engineering of SOX2 with Kruppel-associated box and DNA methyltransferase3A/L catalytic domains to create SES.
- In vitro and in vivo testing of SES on glioma cell lines, cancer stem cells, and mouse xenografts.
- Local viral delivery of SES for tumor treatment.
Main Results:
- SES induces transcriptional silencing of SOX2 targets, leading to cell death in glioma and cancer stem cells.
- In vivo, SES expression caused significant tumor regression and improved survival in mouse xenografts.
- SES demonstrated safety, sparing neurons and glia due to targeted expression in mitotically active cells.
Conclusions:
- SES effectively represses aggressive brain tumors by silencing the SOX2 network.
- SES represents a promising therapeutic strategy for glioblastoma multiforme.
- Targeted delivery and minimal promoter design enhance SES safety and efficacy.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Pleiotropy
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

